Wells Fargo raised the firm’s price target on Icon (ICLR) to $245 from $220 and keeps an Equal Weight rating on the shares following quarterly results. The firm has a neutral relative view of the acquisition of PRA Health Sciences (PRAH) and cites continued pharma/biotech industry trends.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ICLR:
